The purpose of this trial is to assess the safety of a Meningococcal Group B Vaccine and to collect blood donation. Sera panel obtained from blood donations will be used as a control to measure the immunoresponse to the Meningococcal Group B Vaccine in other studies.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
55
One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
01, Novartis Investigational Site
Krakow, Poland
Number of Subjects Reporting Unsolicited Adverse Events (AEs).
Safety was assessed as the number of the subjects who reported unsolicited AEs following vaccination.
Time frame: From day 1 to day 7 after each vaccination (Vaccination 1: Day 1 to Day 7; Vaccination 2: Day 61 to Day 67)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.